Merck & Co (MRK) Earnings Date & Reports

Key Takeaways

• Merck reported second-quarter 2026 revenue of $16.6 billion, up 5% year over year and above the consensus estimate of roughly $16.4 billion.
• Non-GAAP (non-Generally Accepted Accounting Principles) earnings came in at a loss of $0.13 per share, a narrower loss than the roughly $0.26 per share analysts had expected.
• The quarterly loss was driven by a $2.31 per share charge tied to the roughly $5.7 billion acquisition of Terns Pharmaceuticals, rather than any weakness in the core business.
• The KEYTRUDA oncology franchise reached $8.4 billion in sales, up 5%, while newer launches such as WINREVAIR and WELIREG grew sharply.
• Management raised and narrowed its full-year 2026 revenue guidance to $66.3–$67.3 billion and set non-GAAP earnings per share (EPS) guidance at $2.66–$2.76.

Earnings Context and Why It Matters

Merck & Co., Inc. (NYSE: MRK) entered its second-quarter report at a pivotal moment, balancing the mature strength of its KEYTRUDA immunotherapy franchise against a concentrated push to diversify through new launches and strategic deals. Investors were watching closely to see whether double-digit growth from products such as WINREVAIR and WELIREG could offset the financial drag from a large acquisition. Because the quarter included a substantial one-time charge, the headline loss masked what was otherwise a solid top-line beat and constructive outlook. The results matter because they offer an early read on whether Merck can sustain growth ahead of KEYTRUDA's eventual loss of market exclusivity later this decade.

Reported Results

Merck reported second-quarter 2026 worldwide sales of $16.607 billion, an increase of 5% from $15.806 billion a year earlier (4% excluding the impact of foreign exchange), exceeding analyst expectations. Pharmaceutical sales rose 5% to $14.76 billion, while Animal Health sales increased 8% to $1.775 billion.

On the bottom line, the company posted a non-GAAP loss of $0.13 per share, compared with earnings of $2.13 per share in the prior-year quarter. GAAP (Generally Accepted Accounting Principles) EPS was a loss of $0.54, versus earnings of $1.76 a year ago. Both figures reflected a $2.31 per share charge related to the completed acquisition of Terns Pharmaceuticals, a deal that added a clinical-stage hematology asset to the pipeline. Excluding that charge, the underlying business performed ahead of consensus expectations.

Product highlights included KEYTRUDA and KEYTRUDA QLEX sales of $8.366 billion (up 5%), WINREVAIR at $588 million (up 75%), WELIREG at $271 million (up 67%), and CAPVAXIVE at $184 million (up 40%). GARDASIL sales were $1.169 billion, up 4%.

For the full year, Merck raised and narrowed its revenue guidance to $66.3–$67.3 billion and reaffirmed non-GAAP EPS guidance of $2.66–$2.76, a range that includes the one-time acquisition charge.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking pharmaceutical names such as Merck, it can help surface comparable companies and emerging technical setups. Explore the AI Screener to refine your market research.

Market Reaction and Investor Sentiment

The market's initial response to Merck's report was modestly positive. Shares rose roughly 1.4% in premarket trading on August 4, 2026, as investors focused on the "clean" earnings beat, resilient oncology sales, and the upward revision to full-year revenue guidance rather than the headline loss caused by the acquisition charge. Sentiment was further supported by a series of regulatory milestones, including U.S. Food and Drug Administration (FDA) approval of LIPFENDRA, the company's first oral PCSK9 inhibitor for cholesterol lowering, and expanded indications for KEYTRUDA and KEYTRUDA QLEX. Still, some caution persisted around moderating U.S. KEYTRUDA growth and near-term inventory dynamics in certain products, which tempered enthusiasm in the days following the report.

Forward Outlook and Key Factors to Monitor

Looking ahead, investors will focus on whether Merck can convert its pipeline momentum into sustained top-line growth. Management's raised revenue guidance of $66.3–$67.3 billion signals confidence, but the full-year EPS range of $2.66–$2.76 remains weighed down by acquisition-related charges.

Several items deserve attention. First, the trajectory of the KEYTRUDA franchise remains central; U.S. growth is expected to moderate as earlier-stage indications mature, so investors should monitor international expansion and the uptake of KEYTRUDA QLEX. Second, newly launched products such as WINREVAIR, WELIREG, and LIPFENDRA will be watched as the next growth engines, alongside the sac-TMT antibody-drug conjugate program, which reported positive late-stage data.

Cost trends are another factor. Research and development (R&D) spending rose sharply, partly due to the Terns transaction, and any further deal activity could pressure margins in the near term. Finally, currency movements and the timing of vaccine purchases in international markets may introduce quarterly volatility. Merck's next earnings report is expected around late October 2026, when investors will assess whether these dynamics are playing out as guided.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations